Evidence map›Paper›PMID 36863695›Full record

ArticleJournal of immunological methods2023

A modified ELISA assay differentiates CCL20 locked dimers from wild-type monomers.

Xuesong Wu, William R Clarke, Chad A Koplinski, Francis C Peterson, Michael B Dwinell, Grace Wei, Ellen Chao, Mindy Huynh, Daisuke Yamada, Brian F Volkman and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunological methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Xuesong WuDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
William R ClarkeXLock Biosciences, LLC, West Allis, WI, USA; Boston Children's Hospital, Boston, MA, USA.
Chad A KoplinskiDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA; XLock Biosciences, LLC, West Allis, WI, USA.
Francis C PetersonDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA; XLock Biosciences, LLC, West Allis, WI, USA.
Michael B DwinellDepartment of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA.
Grace WeiUSF Health Morsani College of Medicine, Tampa, FL, USA.
Ellen ChaoCalifornia Northstate University, College of Medicine, Elk Grove, CA, USA.
Mindy HuynhDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Daisuke YamadaDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.
Brian F VolkmanDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA; XLock Biosciences, LLC, West Allis, WI, USA.
Samuel T HwangDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA. Electronic address: sthwang@ucdavis.edu.
University of California, Davis · USMedical College of Wisconsin · USAurora West Allis Medical Center · USBoston Children's Hospital · USCalifornia Northstate University · USUniversity of South Florida · US

Funding

Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasisR44AR074363 · NIAMS · XLOCK BIOSCIENCES, LLC · PI KOPLINSKI, CHAD ALLEN, VOLKMAN, BRIAN F · 2020 to 2021
$1.7M
Development of an engineered CCL20 protein as a lead therapeutic molecule for PsoriasisR43AR074363 · NIAMS · PROTEIN FOUNDRY, LLC · PI GETSCHMAN, ANTHONY E, VOLKMAN, BRIAN F · 2018 to 2018
$225k
NIAMS NIH HHS R43 AR074363NIAMS NIH HHS R44 AR074363
6 · The paper itself

Abstract

A novel engineered CCL20 locked dimer (CCL20LD) is nearly identical to the naturally occurring chemokine CCL20 but blocks CCR6-mediated chemotaxis and offers a new approach to treat the diseases of psoriasis and psoriatic arthritis. Methods for quantifying CCL20LD serum levels are needed to assess pharmacokinetics parameters and evaluate drug delivery, metabolism, and toxicity. Existing ELISA kits fail to discriminate between CCL20LD and the natural chemokine, CCL20WT (the wild type monomer). Herein, we tested several available CCL20 monoclonal antibodies to be able to identify one clone that can be used both as a capture and a detection antibody (with biotin-labeling) to specifically detect CCL20LD with high specificity. After validation using recombinant proteins, the CCL20LD-selective ELISA was used to analyze blood samples from CCL20LD treated mice, demonstrating the utility of this novel assay for preclinical development of a biopharmaceutical lead compound for psoriatic disease.

Indexed as

Chemokine CCL20PsoriasisAnimalsAntibodies, MonoclonalChemotaxisEnzyme-Linked Immunosorbent AssayMiceAntibodies, MonoclonalChemokine CCL20CytokineELISALocked dimerPsoriasis

Identifiers

PMID36863695
PMCPMC10715733
OpenAlexW4322627148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.